CANF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CANF is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some bullish analyst support, but the current technical setup is still weak, there is no fresh news catalyst, no strong proprietary trading signal, and no recent financial quarter data to support confident long-term accumulation. If the investor is impatient and wants a clear entry now, the data does not justify an outright buy.
The current price is 3.11, slightly below the previous close of 3.16. Technicals remain bearish overall: MACD histogram is negative at -0.0359, RSI_6 is 35.061, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is also sitting near support at S1 3.141, which means it is close to a possible short-term floor, but it has not yet shown a convincing reversal. The stock trend model suggests modest upside probabilities over the next day, week, and month, but this is not strong enough to override the broader weak trend.
Analyst sentiment improved recently: D. Boral Capital upgraded CANF to Buy with a $7 target, and H.C. Wainwright raised its target to $5 while keeping a Buy rating. Both comments indicate renewed optimism around the company’s clinical pipeline and oncology opportunity. The stock is also near support, which may attract short-term buyers.
There is no recent news in the past week, so there is no fresh event-driven catalyst. Technical momentum is weak, the broader moving average structure is bearish, hedge fund and insider activity are neutral, and there is no recent congress trading data. Post-market action was also negative at -1.58%, showing some immediate selling pressure.
No financial snapshot was available because the financial data returned an error, so the latest quarter season and growth trends cannot be assessed from the provided information.
Analyst sentiment has improved sharply in the last few days. On 2026-05-13, D. Boral Capital upgraded Can-Fite Biopharma to Buy from Hold with a $7 price target. On 2026-05-12, H.C. Wainwright raised its target to $5 from $2.50 and kept a Buy rating. The Wall Street pros view is more positive than before, mainly due to reduced reverse-split technical pressure and renewed focus on the clinical pipeline. However, the lack of confirming price strength means the bullish analyst view is not yet fully supported by market action.
